Larvol Delta - Cell-Therapy-product-sales-decreased-14-to-417-million-in-the-second-quarter-2026-compared-to-the-same-period-in-2025-reflecting-ongoing-competitive-headwinds

Tecartus (brexucabtagene autoleucel) - Gilead

Yescarta (axicabtagene ciloleucel) - Gilead

https://www.businesswire.com/news/home/20260804436824/en/CORRECTING-and-REPLACING-Gilead-Sciences-Announces-Second-Quarter-2026-Financial-Results

Aug 4, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next